HomeClinical TopicsFDA drug approvals

FDA drug approvals

On Jan. 28, the Food and Drug Administration (FDA) approved:

  • Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Read more.
  • Halaven (eribulin mesylate) for the treatment of liposarcoma that is unresectable or metastatic. Treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...